CEL-SCI Corporation Board of Directors

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Mr. Geert R. Kersten Esq.

Mr. Geert R. Kersten Esq.

CEO, Treasurer & Director

Dr. Daniel H. Zimmerman Ph.D.

Dr. Daniel H. Zimmerman Ph.D.

Senior Vice President of Research & Cellular Immunology

Ms. Patricia B. Prichep

Ms. Patricia B. Prichep

Chief Financial and Operations Officer & Corporate Secretary

Dr. Giovanni Selvaggi M.D.

Dr. Giovanni Selvaggi M.D.

Acting Chief Medical Officer

Dr. Eyal Talor Ph.D.

Dr. Eyal Talor Ph.D.

Chief Scientific Officer

Mr. John Cipriano

Mr. John Cipriano

Senior Vice President of Regulatory Affairs

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.